Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition

Detalhes bibliográficos
Autor(a) principal: Härter, Jéssica
Data de Publicação: 2023
Outros Autores: Souza Muza, Letícia, Machado Xavier, Ricardo, André Monticielo, Odirlei
Tipo de documento: Artigo
Idioma: por
Título da fonte: Clinical and Biomedical Research
Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/125709
Resumo: Systemic Lupus Erythematosus (SLE) is an autoimmune disease featuring pleomorphic clinical manifestations whose etiology basically depends on the abnormalities in the functioning of the immunological system coupled to environmental and hormonal factors characterized by the production of antibodies and immunocomplex deposition. People suffering from SLE are prone to have cardiovascular diseases when compared to people in general. Further, several studies suggest that intestine microbiota may have an important role in the progress of such diseases. Microbiota is generally associated with the functioning of the immunological system whose response gets worse due to intestine dysbiosis which may result in a chronic inflammatory stage and, consequently, great cardiovascular risk. Several authors discuss the mechanism by which response to microbiota takes place and the possibility of dietetic interventions. These may comprise probiotics to modify intestine dysbiosis to thwart the disease´s progress and frequent cardiovascular disorders in the population. Current paper revises the available literature on the relationship between intestine microbiota and its nutritional characteristics in SLE patients and the development of cardiovascular diseases.
id UFRGS-20_dfba1d7324c5d70d5cf8e839ff55b0a7
oai_identifier_str oai:seer.ufrgs.br:article/125709
network_acronym_str UFRGS-20
network_name_str Clinical and Biomedical Research
repository_id_str
spelling Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutritionSystemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutritionLupus Erythematosus, SystemicMicrobiotaCardiovascular diseasesLupus Erythematosus, SystemicMicrobiotaCardiovascular diseasesSystemic Lupus Erythematosus (SLE) is an autoimmune disease featuring pleomorphic clinical manifestations whose etiology basically depends on the abnormalities in the functioning of the immunological system coupled to environmental and hormonal factors characterized by the production of antibodies and immunocomplex deposition. People suffering from SLE are prone to have cardiovascular diseases when compared to people in general. Further, several studies suggest that intestine microbiota may have an important role in the progress of such diseases. Microbiota is generally associated with the functioning of the immunological system whose response gets worse due to intestine dysbiosis which may result in a chronic inflammatory stage and, consequently, great cardiovascular risk. Several authors discuss the mechanism by which response to microbiota takes place and the possibility of dietetic interventions. These may comprise probiotics to modify intestine dysbiosis to thwart the disease´s progress and frequent cardiovascular disorders in the population. Current paper revises the available literature on the relationship between intestine microbiota and its nutritional characteristics in SLE patients and the development of cardiovascular diseases.Systemic Lupus Erythematosus (SLE) is an autoimmune disease featuring pleomorphic clinical manifestations whose etiology basically depends on the abnormalities in the functioning of the immunological system coupled to environmental and hormonal factors characterized by the production of antibodies and immunocomplex deposition. People suffering from SLE are prone to have cardiovascular diseases when compared to people in general. Further, several studies suggest that intestine microbiota may have an important role in the progress of such diseases. Microbiota is generally associated with the functioning of the immunological system whose response gets worse due to intestine dysbiosis which may result in a chronic inflammatory stage and, consequently, great cardiovascular risk. Several authors discuss the mechanism by which response to microbiota takes place and the possibility of dietetic interventions. These may comprise probiotics to modify intestine dysbiosis to thwart the disease´s progress and frequent cardiovascular disorders in the population. Current paper revises the available literature on the relationship between intestine microbiota and its nutritional characteristics in SLE patients and the development of cardiovascular diseases.HCPA/FAMED/UFRGS2023-11-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed ArticleAvaliados por Paresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/125709Clinical & Biomedical Research; Vol. 43 No. 3 (2023): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 43 n. 3 (2023): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSporhttps://seer.ufrgs.br/index.php/hcpa/article/view/125709/90546Copyright (c) 2023 Jéssica Härter, Letícia Souza Muza, Ricardo Machado Xavier, Odirlei André Monticielohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessHärter, JéssicaSouza Muza, LetíciaMachado Xavier, RicardoAndré Monticielo, Odirlei2024-01-19T13:25:12Zoai:seer.ufrgs.br:article/125709Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T13:25:12Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
title Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
spellingShingle Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
Härter, Jéssica
Lupus Erythematosus, Systemic
Microbiota
Cardiovascular diseases
Lupus Erythematosus, Systemic
Microbiota
Cardiovascular diseases
title_short Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
title_full Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
title_fullStr Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
title_full_unstemmed Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
title_sort Systemic erythematous lupus and gut microbiota: a review on its relationship with the development of cardiovascular diseases from the point of view of clinical nutrition
author Härter, Jéssica
author_facet Härter, Jéssica
Souza Muza, Letícia
Machado Xavier, Ricardo
André Monticielo, Odirlei
author_role author
author2 Souza Muza, Letícia
Machado Xavier, Ricardo
André Monticielo, Odirlei
author2_role author
author
author
dc.contributor.author.fl_str_mv Härter, Jéssica
Souza Muza, Letícia
Machado Xavier, Ricardo
André Monticielo, Odirlei
dc.subject.por.fl_str_mv Lupus Erythematosus, Systemic
Microbiota
Cardiovascular diseases
Lupus Erythematosus, Systemic
Microbiota
Cardiovascular diseases
topic Lupus Erythematosus, Systemic
Microbiota
Cardiovascular diseases
Lupus Erythematosus, Systemic
Microbiota
Cardiovascular diseases
description Systemic Lupus Erythematosus (SLE) is an autoimmune disease featuring pleomorphic clinical manifestations whose etiology basically depends on the abnormalities in the functioning of the immunological system coupled to environmental and hormonal factors characterized by the production of antibodies and immunocomplex deposition. People suffering from SLE are prone to have cardiovascular diseases when compared to people in general. Further, several studies suggest that intestine microbiota may have an important role in the progress of such diseases. Microbiota is generally associated with the functioning of the immunological system whose response gets worse due to intestine dysbiosis which may result in a chronic inflammatory stage and, consequently, great cardiovascular risk. Several authors discuss the mechanism by which response to microbiota takes place and the possibility of dietetic interventions. These may comprise probiotics to modify intestine dysbiosis to thwart the disease´s progress and frequent cardiovascular disorders in the population. Current paper revises the available literature on the relationship between intestine microbiota and its nutritional characteristics in SLE patients and the development of cardiovascular diseases.
publishDate 2023
dc.date.none.fl_str_mv 2023-11-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article
Avaliados por Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/125709
url https://seer.ufrgs.br/index.php/hcpa/article/view/125709
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/125709/90546
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 43 No. 3 (2023): Clinical and Biomedical Research
Clinical and Biomedical Research; v. 43 n. 3 (2023): Clinical and Biomedical Research
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1799767057410031616

Registros relacionados